Yong Rong (HK) Asset Management’s Legend Biotech LEGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-130,000
Closed -$6.06M 8
2021
Q4
$6.06M Buy
130,000
+100,249
+337% +$5.09M 4.79% 9
2021
Q3
$1.5M Buy
+29,751
New +$1.24M 0.99% 13
2021
Q2
Sell
-198,312
Closed -$5.76M 19
2021
Q1
$5.76M Hold
198,312
1.58% 11
2020
Q4
$5.58M Buy
198,312
+153,312
+341% +$4.41M 1.5% 9
2020
Q3
$1.39M Buy
+45,000
New +$1.52M 0.95% 9

Other funds holding LEGN

Yong Rong (HK) Asset Management's LEGN Position: Q1 2022 in Review

Yong Rong (HK) Asset Management sold out of Legend Biotech (LEGN) in Q1 2022, closing a stake of 130,000 shares — an estimated $6.06M sold.

Yong Rong (HK) Asset Management first reported a position in LEGN in Q3 2020 and held it in 5 quarters. The position peaked at $6.06M in Q4 2021. 141 funds tracked by Wall St. Rank hold LEGN as of Q1 2022.

  • Yong Rong (HK) Asset Management reported no remaining Legend Biotech position as of Q1 2022 after selling out during the quarter.
  • Yong Rong (HK) Asset Management sold 130,000 Legend Biotech shares in Q1 2022, an estimated $6.06M.
  • Yong Rong (HK) Asset Management first reported a position in Legend Biotech in Q3 2020 and held it in 5 quarters.
  • Yong Rong (HK) Asset Management's Legend Biotech position peaked at $6.06M in Q4 2021.
  • 141 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2022.

Based on Yong Rong (HK) Asset Management's 13F filing for Q1 2022, filed 4 May 2022.